Susie Li

Multiple‐Dose Pharmacokinetics, Pharmacodynamics, and Safety of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, in Healthy Male Volunteers

Carol Addy, Paul Rothenberg, Susie Li et al. · The Journal of Clinical Pharmacology · 2008 · 49 citations · Full text

Accumulation Half-life, Pharmacotherapy, Multiple-dose Pharmacokinetics +17

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

Walter J. Loos, Ronald de Wit, Steven J. Freedman et al. · Cancer Chemotherapy and Pharmacology · 2006 · 47 citations

Vinorelbine Pharmacokinetics, Medicine, Pharmacology +8

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers

Carol Addy, Susie Li, Nancy Agrawal et al. · The Journal of Clinical Pharmacology · 2008 · 47 citations

Pharmacokinetics, Safety, and Tolerability of Phentermine in Healthy Participants Receiving Taranabant, a Novel Cannabinoid‐1 Receptor (CB1R) Inverse Agonist

Carol Addy, Patricia Jumes, Kimberly Rosko et al. · The Journal of Clinical Pharmacology · 2009 · 13 citations

Inverse Agonist, Pharmacotherapy, Cannabinoid Pharmacology +16

Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects

Rajesh Krishna, Daria Stypinski, Melissa Ali et al. · Biopharmaceutics & Drug Disposition · 2011 · 12 citations · Full text

Molecular Pharmacology, Digoxin C, Therapeutic Drug Monitoring +12